PCVX — Vaxcyte, Inc.
Is PCVX overbought or oversold? Here is the current MarketMoodz read.
Vaxcyte, Inc. (PCVX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $61.61. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$61.61
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Vaxcyte, Inc. (PCVX) is a pipeline-focused vaccine company whose near-term equity performance will be driven by clinical readouts, regulatory milestones, and financing outcomes. The company benefits from targeted vaccine assets and potential partner or acquirer interest, but its valuation remains sensitive to binary development outcomes and the need for additional capital. Market context is a cautious risk-on tone favoring larger, defensive pharma names, which can limit momentum for smaller vaccine developers. Key upside scenarios include positive clinical/regulatory progress or strategic partnerships; downside scenarios center on clinical setbacks, dilution from capital raises, manufacturing or reimbursement challenges, and intensified competition.
Key factors
- Pipeline-driven value: near- and mid-term clinical readouts and regulatory milestones will be primary drivers of valuation and volatility.
- Limited diversification of revenue sources relative to large-cap pharma, increasing sensitivity to success/failure of lead programs.
- Cash runway and financing posture: potential need to raise capital in a higher-volatility biotech funding environment could dilute shareholders or change timing for programs.
- Partnership and M&A optionality: strategic collaborations or acquisition interest from larger vaccine/biopharma players can be a positive optionality if programs advance.
- Sector-wide flows favoring large-cap, defensive pharma reduce near-term relative interest in smaller vaccine developers, limiting momentum.
- Macroeconomic/regulatory backdrop is cautious risk-on; investor focus on policy signals and earnings season may reduce conviction for aggressive biotech positioning.
Risks
- Clinical development setbacks or regulatory delays for lead vaccine candidates, which would materially reduce near-term valuation.
- Need to raise additional capital leading to dilution or unfavorable financing terms.
- Commercial execution and manufacturing scale-up challenges if/when products approach commercialization.
- Strong competition from established large-cap vaccine and biologics manufacturers with greater commercial reach and pricing power.
- Reimbursement and pricing pressure from payors and policy/regulatory changes that could constrain vaccine pricing or uptake.
- Broader market volatility or risk-off moves that disproportionately impact small-to-mid cap biotech equities.
See today's live rating, score and targets
Members see the live hourly rating for PCVX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.